A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting

NCT02493777 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

125

Enrollment

OTHER

Sponsor class

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

DRUG: HLD200 methylphenidate hydrochloride (MPH) Capsules
DRUG: Placebo

Sponsor

Ironshore Pharmaceuticals and Development, Inc